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At last, a mouse model of the natural history of chronic myeloid leukemia (CML) has been elegantly engineered.
CML is hardly a public health menace, occurring in only 1–2 per 100,000 people. Nonetheless, the disease is 
the “poster child” of genetically based diagnosis and treatment, as all cases of CML have the BCR-ABL trans-
location, which is both a diagnostic marker of the disease and a target for tyrosine kinase inhibitor (TKI) therapy. 
CML is usually diagnosed in the so-called chronic phase, characterized by an expansion of circulating mature 
myeloid cells. Without treatment, all CML cases will eventually accumulate new mutational events, progressing 
first into accelerated phase and then to a fatal blast phase. The advent of TKI therapy has made a major impact on 
the natural history of chronic phase disease, and few patients now progress on therapy. However, some do, and 
still other patients actually present with advanced phase disease. For these patients, therapeutic options are limited 
and generally ineffective.
The genetic “clock” that drives CML progression is unknown, and this limits development of diagnostic tools to predict pro-
gression and therapeutic options to block or treat it. A major part of this limitation is the lack of mouse models of CML that 
accurately simulate human CML. Most mouse CML models quickly develop an acute leukemia, often of the lymphoid lineage 
(unlike CML blast crisis, which is predominantly myeloid), or stay in a chronic phase. In this issue, Giotopoulos et al. provide a 
major contribution to the field by developing a cleverly engineered mouse model that quite faithfully duplicates human CML.
Their mouse model has both inducible BCR-ABL and “Sleeping Beauty” transposon elements, allowing them to first 
activate BCR-ABL (mimicking chronic phase), and later to activate transposon-based insertional mutagenesis (mimicking 
progression). The model shows many features of 
human CML, including progression from chronic 
phase to a predominantly myeloid blast crisis, ex-
pansion of the hematopoetic stem cell and progenitor 
cell compartments, and similar changes in gene ex-
pression from chronic to blast phase as those reported 
in human samples (much to the relief of both mouse 
and human investigators!).
The authors find a role for pathways that are 
potentially targetable by existing and investigational 
agents, including ERG, MYC, MEK, RAF, and 
JAK1/2. This will likely lead to the rapid development 
of mouse models in which to study whether such 
agents can either treat or prevent blast crisis. Because 
the therapeutic options for humans with advanced 
phase are severely limited (with curative potential lim-
ited to allogeneic transplantation), the findings from 
this paper will also likely quickly lead to the study of 
these pathways in patients with advanced phase disease, 
with possible intervention in those cases where acti-
vation can be demonstrated. The outcome for patients 
with blast crisis has remained relatively static for 
decades. The findings from this strong manuscript 
suggest that may soon change.
Giotopoulos, G., et al. 2015. J. Exp. Med. http://dx.doi 
.org/10.1084/jem.20141661
Major progress in understanding progression in chronic 
myeloid leukemia
Insight from 
Jerry Radich
A highly simplified model of CML progression. A genotoxic insult (lightening 
bolt) cases the BCR-ABL translocation. BCR-ABL induces myeloid proliferation 
and also results in genomic instability. Without therapy, unopposed BCR-
ABL signaling causes new chromosomal changes, mutations, and changes in 
gene expression, causing a block in differentiation, further increases in cell 
cycling, and decreased apoptosis. In the figure, *** indicates the genetic 
changes in addition to BCR-ABL that promote progression to advanced phase 
CML (accelerated and blast phases). The “index of progression” is an artificial 
construct suggesting the cumulative affect of many changes in gene struc-
ture and function.
Jerry Radich, MD, Fred Hutchinson Cancer Research Center: jradich@fredhutch.org
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In this issue, Giacomin et al. report on a novel function of IKKa acting in intestinal epithelial 
cells (IECs) to control intestinal immunity against enteropathogenic bacteria. Human entero-
pathogenic and enterohemorrhagic E. coli constitute a serious health concern, as they can cause 
life-threatening intestinal infections. Infection of mice with Citrobacter rodentium, a natural 
enteric mouse pathogen, serves as a relevant model to study the mechanisms of host immunity 
against this family of enteropathogenic bacteria.
Giacomin et al. found that mice with IEC-specific ablation of IKKa (IKKaDIEC), but 
not IKKb, were highly susceptible to C. rodentium infection. A series of elegant follow-up 
experiments revealed that epithelial IKKa deficiency caused impaired production of IL-22, 
a cytokine that promotes epithelial regeneration and antimicrobial defense, by group 3 
innate lymphoid cells (ILC3s) in infected mice. Administration of recombinant IL-22 or transfer of IL-22 producing ILCs 
restored effective immunity to C. rodentium in IKKaDIEC mice. The IKKa-deficient epithelium produced increased amounts 
of TSLP, and treatment with neutralizing antibodies against TLSP largely restored IL-22 production and effective immunity 
to C. rodentium. Interestingly, recombinant TSLP inhibited IL-22 production by RORgt+ ILCs when added in splenocyte 
cultures but not in purified ILC cultures, suggesting that 
the suppressive effect of TSLP on IL-22 production in 
ILCs is indirect.
The study by Giacomin et al. adds novel insight to our 
understanding of the epithelial–immune cell dialog that 
controls intestinal immunity, but it also raises new ques-
tions. Does epithelial IKKa act via noncanonical NF-kB 
signaling, as suggested by previous studies implicating epi-
thelial lymphotoxin b receptor and stromal p52 in control-
ling C. rodentium infection, or do other, NF-kB–independent, 
IKKa functions regulate intestinal immunity? Additional 
studies in mice with epithelial cell specific knockout of 
specific NF-kB subunits will be required to address this 
question. The target cell type that responds to TSLP and 
suppresses IL-22 production by ILCs also remains to be 
identified. Dendritic cells (DCs) are a likely candidate, as 
TSLP affects DC polarization and cytokine production, 
which could in turn affect IL-22 expression by ILCs. 
Moreover, TSLP neutralization only partly restored im-
munity to C. rodentium in IKKaDIEC mice, suggesting that 
additional, as yet unknown, mechanisms also contribute. 
From a clinical perspective, this study raises the interesting 
possibility that TSLP neutralization might have beneficial 
effects in enteropathogenic bacterial infections, although 
the diverse biological functions of TSLP may make it 
difficult to exploit this newly identified mechanism 
therapeutically.
Giacomin, P.R., et al. 2015. J. Exp. Med. http://dx.doi.org/10.1084/jem.20141831
Upon infection with C. rodentium, IKKa-deficient IECs increase their pro-
duction of TSLP, which inhibits IL-22 production by RORgt+ ILCs indirectly 
by acting on an as yet unknown cell type (possibly dendritic cells). Dimin-
ished IL-22 production in turn decreases expression of the antimicrobial 
proteins REG3b and REG3g and impairs epithelial regeneration.
Christina Eftychi and Manolis Pasparakis, Institute for Genetics and CECAD Research Center, University of Cologne: pasparakis@uni-koeln.de
Epithelial IKKa licenses ILC3s to defend the intestinal bar r ier
Insight from Christina Eftychi (left) 
and Manolis Pasparakis (right)
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Induction of broadly neutralizing antibodies against rapidly evolving viruses is a “holy grail” of current vac-
cine research. A study in this issue reveals that it’s not just the properties of the immunogen that matter, but 
also the anatomical site of the B cell response.
Influenza infection causes substantial morbidity and mortality each year despite the wide use of an 
annually updated vaccine. A major limitation of the current vaccination approach is the weak ability to 
induce antibodies that recognize variant forms of the hemagglutinin (HA) antigen, which arise continu-
ally by antigenic drift (point mutations in an existing strain) and more rarely by antigenic shift (major 
changes in the HA gene by viral mixing). In this issue, Adachi et al. examine the requirements for the 
generation of cross-reactive antibodies that recognize different influenza strains. By comparing the 
properties of germinal center (GC) and memory B cells (Bmem) isolated from lung, draining LNs, and 
spleen of intranasally infected mice, they discovered that cross-reactive B cells are preferentially generated in the lung. 
Using conditional Bcl6 ablation, they established that ongoing GC responses are needed for generation of these late-
arising cross-reactive memory cells. Using a novel procedure of intratracheal exposure to low amounts of 5-ethynyl-20-
deoxyuridine (EdU) to locally label dividing cells, they show that cross-reactive Bmem are preferentially generated and 
maintained in the lung.
Although GCs are most readily induced in secondary lymphoid organs, they can also form ectopically at sites of inflam-
mation. Remarkably, this study shows that ectopic GC formation doesn’t just provide additional antibody-generating 
capacity, it provides a qualitatively 
unique environment tailored for the 
induction of cross-reactive antibodies. 
As the authors suggest, the enhanced 
cross-reactive Bmem induction in the 
lung might reflect the presence of 
greater amounts of viral antigen, 
drifted variants that arose before the 
virus was cleared, or forms of HA that 
are more accessible to the BCR. It 
will be exciting to see whether these 
factors operate together to make the 
local response the most efficacious.
Interestingly, the proliferation rate 
of HA-binding GC B cells in the lung 
was greater than in LNs and spleen. The 
basis for this effect was not examined 
but might reflect properties associated 
with the inflammatory milieu or per-
haps even the higher oxygen levels in 
the lung. Whatever the explanation, the 
faster proliferation rate may contribute 
to more rapid accrual of mutations and 
possibly greater diversification of the 
Bmem pool that is generated. While the mechanistic studies move forward, this work is a reminder that anatomy and not just 
molecular components matter in the efforts to develop vaccine strategies that induce broadly neutralizing antibody responses.
Adachi, Y., et al. 2015. J. Exp. Med. http://dx.doi.org/10.1084/jem.20142284
Anatomical differences that may contribute to induction of influenza strain cross-reactive 
B cells in the lung. The diagram on left shows paths of antigen (Ag) travel and sites of GC 
formation (iBALT, induced bronchial-associated lymphoid tissue, appears about 1 week after 
infection), which differ in the generation of HA-binding, cross-reactive GC B cells (green) at 
day 30 after intranasal infection with influenza A virus X31. The table summarizes key dif-
ferences between sites, including the timing of the peak GC response, amount and form of Ag 
remaining at day 30, Ig mutation load (Bmem mutations), and the presence of cross-reactive 
Bmem. Data on the peak GC response, Ig mutation load, and cross-reactive B cell frequencies 
are based on the findings reported in Adachi et al.
Jason G. Cyster, Howard Hughes Medical Institute and University of California, San Francisco: Jason.Cyster@ucsf.edu
Getting close to the action elicits better memor ies
Insight from 
Jason Cyster
JEM Vol. 212, No. 10 1485
Celiac disease (CD) arises from inflammatory T cell and antibody responses to 
dietary gluten in a genetically susceptible host. CD is notable for a distinct 
pattern of histological injury to intestinal epithelial cells (IECs) characterized 
by crypt hyperplasia and atrophy of the villi, which is caused by infiltrating 
intraepithelial cytotoxic CD8+ T cells (IE-CTLs).
CD is antigen driven and strongly restricted to particular MHC class II 
alleles such that antigen (gluten) elimination is a recognized therapy. How-
ever, emerging data suggest that the “final hit” to disease progression is through 
downstream noncognate events that are orchestrated by the MHC class II 
response and may be part of a common spectrum of immune pathways shared 
with multiple diseases such as inflammatory bowel disease, graft-versus-host disease, and infectious enteritis. Specifically, gluten 
promotes interleukin-15 (IL-15) expression by distressed IECs via yet to be defined mechanisms. IL-15 in turn recruits addi-
tional IE-CTLs to the epithelium and arms these cells by increasing the expression of the activating receptor natural killer group 2 
member D (NKG2D). NKG2D ligands, such as MHC class I chain related A and B (MICA/B), are displayed on stressed cells, 
resulting in their cytolysis by the NKG2D-expressing IE-CTLs, thus setting up a continuous cycle of IEC destruction.
In this issue, Tang et al. follow up on previous observa-
tions showing that NKG2D-mediated cytolysis depends on 
intracellular signaling via cytosolic phospholipase A2 (cPLA2), 
which catalyzes release of arachidonic acid (AA) from the 
membrane. Unexpectedly, they find that the NKG2D-
induced cPLA2 and IL-15 signaling pathways converge on the 
production of leukotrienes, AA metabolites that have been 
previously linked to allergic disorders including asthma. They 
find that NKG2D ligation up-regulates an enzymatic cascade 
associated with 5-lipoxygenase and leukotriene C4 synthase 
(LTC4S), leading to production of cysteinyl leukotrienes 
(CystLTs) and the expression of the CystLT receptor on effec-
tor cells. Not only do they demonstrate that pharmacological 
inhibition or siRNA knockdown of enzymes involved in the 
CystLT pathway significantly impair NKG2D-mediated killing, 
they show that CystLT up-regulation is demonstrable in patients 
with active CD but not in healthy controls or in patients on 
a gluten-free diet.
An FDA-approved CystLT inhibitor, montelukast, is ben-
eficial in patients with asthmatic disease, and the authors show 
that in vitro pretreatment of IE-CTL lines with montelukast 
significantly decreases their cytolytic capacity. These experi-
ments unravel an unexpected role for CystLTs in NKG2D-
mediated cytolysis and also open up a potential new therapeutic 
approach for CD that is eminently testable. These exciting 
results not only underline the benefits of careful and painstaking 
interrogation of complex signaling pathways but also the oppor-
tunities that can be derived from applying clinical insights 
across widely disparate organ-associated diseases.
Tang, F., et al. 2015. J. Exp. Med. http://dx.doi.org/10.1084/jem.20150303
Interaction of NKG2D on IE-CTLs with its ligands expressed on 
distressed IECs results in a cascade of reactions ultimately leading 
to increased levels of CystLTs, which is responsible for IEC killing, 
as observed in patients with CD. Inhibiting CystLTs might decrease 
IE-CTL cytotoxic capacity and could therefore be an interesting new 
therapeutic approach in patients with CD.
Joep Grootjans, Shuhei Hosomi, and Richard S. Blumberg, Brigham and Women’s Hospital, Harvard Medical School: rblumberg@partners.org
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